Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp®

NACompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

March 17, 2022

Primary Completion Date

June 21, 2024

Study Completion Date

June 21, 2024

Conditions
Type 1 Diabetes
Interventions
DEVICE

MiniMed 780G System

780G System used with Insulin Fiasp® (Insulin Aspart Injection)

Trial Locations (18)

2305

John Hunter Childrens Hospital, New Lambton

21229

Barry J Reiner MD, LLC, Baltimore

27834

Physicians East, Greenville

30076

Endocrine Research Solutions, Roswell

30318

Atlanta Diabetes Associates, Atlanta

33612

University of South Florida, Tampa

72211

Medical Investigations, Inc., Little Rock

78229

Diabetes and Glandular Disease Clinic, P.A., San Antonio

80045

Barbara Davis Center for Diabetes, Aurora

83404

Rocky Mountain Clinical Research, Idaho Falls

89113

The Docs, LLC, Las Vegas

92123

Rady's Children's Hospital, San Diego

93720

Valley Research, Fresno

95821

Sutter Institute for Medical Research, Sacramento

98057

Rainier Clinical Research Center, Renton

98405

MultiCare Institute for Research & Innovation, Tacoma

T3B 6A8

Alberta Children's Hospital Research Institute, Calgary

M4G 3E8

LMC Clinical Research, Toronto

All Listed Sponsors
lead

Medtronic Diabetes

INDUSTRY